fingolimod
E518759
disease-modifying therapy
immunomodulatory drug
multiple sclerosis medication
small molecule drug
sphingosine 1-phosphate receptor modulator
Fingolimod is an oral disease-modifying immunomodulatory drug used to reduce relapses and delay disability progression in people with relapsing forms of multiple sclerosis.
All labels observed (1)
| Label | Occurrences |
|---|---|
| fingolimod canonical | 2 |
How this entity was disambiguated
This entity first appeared as the object of triple T5425242 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: fingolimod Context triple: [relapsing-remitting multiple sclerosis, treatedWith, fingolimod]
-
A.
Tecfidera
Tecfidera is an oral disease-modifying medication used to treat relapsing forms of multiple sclerosis by reducing inflammation and relapse frequency.
-
B.
Tysabri
Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
-
C.
fampridine
Fampridine is a potassium channel blocker medication primarily used to improve walking in adults with multiple sclerosis.
-
D.
Namenda
Namenda is a prescription medication used to treat moderate to severe Alzheimer's disease by regulating the activity of glutamate in the brain.
-
E.
Actemra
Actemra is a prescription biologic medication (tocilizumab) used to treat inflammatory conditions such as rheumatoid arthritis by inhibiting the interleukin-6 (IL-6) receptor.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: fingolimod Target entity description: Fingolimod is an oral disease-modifying immunomodulatory drug used to reduce relapses and delay disability progression in people with relapsing forms of multiple sclerosis.
-
A.
Tecfidera
Tecfidera is an oral disease-modifying medication used to treat relapsing forms of multiple sclerosis by reducing inflammation and relapse frequency.
-
B.
Tysabri
Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
-
C.
fampridine
Fampridine is a potassium channel blocker medication primarily used to improve walking in adults with multiple sclerosis.
-
D.
Namenda
Namenda is a prescription medication used to treat moderate to severe Alzheimer's disease by regulating the activity of glutamate in the brain.
-
E.
Actemra
Actemra is a prescription biologic medication (tocilizumab) used to treat inflammatory conditions such as rheumatoid arthritis by inhibiting the interleukin-6 (IL-6) receptor.
- F. None of above. chosen
Statements (54)
| Predicate | Object |
|---|---|
| instanceOf |
disease-modifying therapy
ⓘ
immunomodulatory drug ⓘ multiple sclerosis medication ⓘ small molecule drug ⓘ sphingosine 1-phosphate receptor modulator ⓘ |
| affectsCellType |
B lymphocytes
ⓘ
T lymphocytes ⓘ |
| approvedBy |
European Medicines Agency
ⓘ
U.S. Food and Drug Administration ⓘ
linked to:
Food and Drug Administration
|
| contraindicatedIn |
certain types of heart block without pacemaker
ⓘ
recent myocardial infarction ⓘ stroke or TIA within 6 months ⓘ unstable angina ⓘ |
| developedBy | Novartis ⓘ |
| hasAdverseEffect |
atrioventricular block
ⓘ
bradycardia ⓘ cough ⓘ diarrhea ⓘ elevated liver enzymes ⓘ headache ⓘ hypertension ⓘ lymphopenia ⓘ macular edema ⓘ |
| hasATCCode | L04AA27 ⓘ |
| hasBlackBoxWarning |
risk of bradycardia
ⓘ
risk of progressive multifocal leukoencephalopathy ⓘ risk of serious infections ⓘ |
| hasBrandName | Gilenya ⓘ |
| hasCASNumber | 162359-56-0 ⓘ |
| hasDosageForm |
oral capsule
ⓘ
oral tablet ⓘ |
| hasFDAApprovalYear | 2010 ⓘ |
| hasGenericName | fingolimod ⓘ |
| hasINN | fingolimod ⓘ |
| hasMechanismOfAction | sphingosine 1-phosphate receptor modulator ⓘ |
| hasMolecularFormula | C19H33NO2 ⓘ |
| hasPharmacologicalEffect |
lymphocyte sequestration in lymph nodes
ⓘ
reduction of circulating lymphocytes ⓘ |
| hasPregnancyRisk | teratogenic potential ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| isMetabolizedTo | fingolimod-phosphate ⓘ |
| isProdrug | true ⓘ |
| regulatesProcess | lymphocyte trafficking ⓘ |
| requiresMonitoring |
heart rate after first dose
ⓘ
liver function tests ⓘ ophthalmologic examination ⓘ |
| targetsReceptor |
S1P1 receptor
ⓘ
S1P3 receptor ⓘ S1P4 receptor ⓘ S1P5 receptor ⓘ |
| therapeuticEffect |
delay of disability progression in multiple sclerosis
ⓘ
reduction of relapse rate in multiple sclerosis ⓘ |
| usedFor |
relapsing forms of multiple sclerosis
ⓘ
relapsing-remitting multiple sclerosis ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: fingolimod Description of subject: Fingolimod is an oral disease-modifying immunomodulatory drug used to reduce relapses and delay disability progression in people with relapsing forms of multiple sclerosis.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.